Mankind Pharma, a leading pharmaceutical company, has announced its expansion into the cat nutrition market with the launch of its Petstar Delight range. This move marks the company’s entry into the pet care industry, specifically targeting the growing demand for high-quality cat food. The Petstar Delight range is designed to provide cats with a nutritious and delicious diet, catering to their unique needs and preferences.

The Petstar Delight range includes a variety of products, such as dry food, wet food, and treats, all formulated to meet the nutritional requirements of cats at different life stages. The products are made with high-quality protein sources, including chicken, salmon, and lamb, and are free from artificial preservatives and flavors. The range also includes grain-free and gluten-free options, catering to cats with dietary sensitivities.

Mankind Pharma’s entry into the pet care industry is a strategic move, given the growing trend of pet humanization and the increasing demand for premium pet food. The company aims to leverage its expertise in pharmaceuticals to create high-quality pet food products that meet the evolving needs of cat owners. The Petstar Delight range is expected to be competitive in the market, offering a unique blend of nutrition, taste, and affordability.

The launch of Petstar Delight is also expected to create new opportunities for Mankind Pharma, allowing the company to tap into the rapidly growing pet care market. The global pet food market is projected to reach $180 billion by 2025, driven by increasing pet ownership and the rising demand for premium pet food. Mankind Pharma’s expansion into this market is likely to contribute to the company’s growth and diversification strategy.

The Petstar Delight range will be available across various channels, including online platforms, pet stores, and veterinary clinics. Mankind Pharma has also planned a comprehensive marketing campaign to promote the brand and create awareness about the importance of providing high-quality nutrition to cats. With the launch of Petstar Delight, Mankind Pharma is poised to become a significant player in the cat nutrition market, offering cat owners a reliable and trustworthy brand that prioritizes their pets’ health and well-being.

Mankind Pharma, a leading pharmaceutical company, has expanded its PetStar brand into the cat food segment with the launch of PetStar Delight. This new range of cat food is designed to support overall feline wellness and marks a significant milestone in the company’s pet care journey, which began with the launch of PetStar dog food in 2022. PetStar Delight is formulated with a powerful blend of functional ingredients, including cranberry, turmeric, and taurine, which provide various health benefits such as urinary health, immunity, and digestive health.

The product is manufactured in Thailand and adheres to stringent quality standards, offering pet parents a clean label option with no artificial colors or preservatives. The PetStar Delight range is available in three flavors – salmon, tuna, and ocean fish – and caters to two distinct life stages: kitten (one to 12 months) and adult (12 months and above). Each life stage has a specific nutritional profile, with the kitten range containing 32% protein and 12% fat, and the adult range containing 30% protein and 10% fat.

According to Rajeev Juneja, Vice Chairman and Managing Director of Mankind Pharma, the company has witnessed the tremendous potential of India’s pet care market and the evolving needs of pet parents since launching PetStar in 2022. With PetStar Delight, the company aims to bring the same commitment to quality, affordability, and wellness that defines its pharmaceutical business and dog food range into feline nutrition. Dr. Piyush Prashant, Vice President and Head of Pet Food Division, Mankind Pharma, added that the company has applied the same commitment to quality for cats as it did for dogs, with each recipe combining superior palatability with functional nutrition.

The PetStar Delight range incorporates ingredients with specific health benefits, such as prebiotic beta-glucans and MOS for gut health, natural fiber for hairball control, and salmon oil for brain development. The company has created a comprehensive solution that addresses the real health concerns of cat owners, making it a significant addition to the pet care market. With the launch of PetStar Delight, Mankind Pharma aims to provide scientifically formulated nutrition that supports the complete health of pets across species and life stages.

A CDSCO (Central Drugs Standard Control Organization) panel has instructed Mankind Pharma to conduct a Phase I clinical trial for Sintilimab Injection in India before proceeding to Phase III trials. Sintilimab is a recombinant humanized monoclonal antibody used for the treatment of certain types of cancer. The decision was made after reviewing the company’s proposal to conduct a Phase III trial for the drug.

Mankind Pharma had submitted a proposal to the CDSCO to conduct a Phase III trial for Sintilimab Injection, which is already approved in China for the treatment of relapsed or refractory classical Hodgkin’s lymphoma. However, the CDSCO panel noted that the company had not conducted any clinical trials for the drug in India and had only submitted data from trials conducted in China.

The panel expressed concerns that the pharmacokinetic and pharmacodynamic data generated from Chinese patients may not be applicable to the Indian population due to differences in genetics, diet, and lifestyle. Therefore, the panel directed Mankind Pharma to conduct a Phase I trial in India to generate data on the safety, tolerability, and pharmacokinetics of the drug in the Indian population.

The Phase I trial will involve a small group of healthy volunteers and will be designed to assess the safety and tolerability of the drug. The trial will also generate data on the pharmacokinetics of the drug, including its absorption, distribution, metabolism, and excretion.

The CDSCO panel’s decision is in line with the regulatory requirements for the approval of new drugs in India, which mandate that clinical trials be conducted in the country to generate data on the safety and efficacy of the drug in the Indian population. The decision also reflects the regulator’s emphasis on ensuring that new drugs are safe and effective for Indian patients before they are approved for marketing.

Mankind Pharma will now have to conduct the Phase I trial and submit the data to the CDSCO before proceeding to the Phase III trial. The company had planned to launch the drug in India by the end of 2023, but the delay in conducting the Phase I trial may push back the launch timeline. The development is significant as it highlights the importance of conducting clinical trials in India to generate data on the safety and efficacy of new drugs in the Indian population.

Mankind Pharma, a leading Indian pharmaceutical company, has been slapped with a Goods and Services Tax (GST) penalty of INR 83 lakh (approximately USD 110,000) by the GST authorities. The penalty was imposed due to alleged irregularities in the company’s GST returns and invoices.

According to reports, the GST authorities conducted an investigation into Mankind Pharma’s financial records and discovered discrepancies in the company’s GST returns and invoices. The authorities alleged that the company had not paid the correct amount of GST on its sales and had also claimed incorrect input tax credits.

As a result, the GST authorities imposed a penalty of INR 83 lakh on the company. Mankind Pharma has stated that it plans to appeal against the penalty, claiming that the allegations are baseless and that the company has complied with all GST regulations.

The company’s management has expressed surprise at the penalty, stating that it has always followed the law and has a robust system in place to ensure compliance with GST regulations. Mankind Pharma has a strong track record of compliance with regulatory requirements and has always maintained transparency in its financial dealings.

The penalty imposed on Mankind Pharma is a significant development in the Indian pharmaceutical industry, which has been facing several challenges in recent times. The industry has been grappling with issues such as price controls, regulatory hurdles, and intense competition, which have impacted the profitability of several companies.

The GST penalty imposed on Mankind Pharma is likely to have a negative impact on the company’s financial performance in the short term. However, the company’s management is confident that it will be able to appeal against the penalty and get it revoked. Mankind Pharma has a strong financial position and a diversified product portfolio, which will help it to weather the challenges posed by the GST penalty.

In conclusion, Mankind Pharma’s GST penalty is a significant development in the Indian pharmaceutical industry. The company plans to appeal against the penalty, and its management is confident that it will be able to get it revoked. The outcome of the appeal will be closely watched by the industry, as it will have implications for the compliance requirements of pharmaceutical companies in India. With its strong financial position and diversified product portfolio, Mankind Pharma is well-equipped to handle the challenges posed by the GST penalty.

Mankind Pharma Limited is a leading pharmaceutical company based in India that specializes in developing, manufacturing, and marketing a wide range of pharmaceutical formulations and consumer healthcare products. The company’s product portfolio is diverse and comprehensive, covering various acute and chronic therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/central nervous system, vitamins, minerals, and nutrients, and respiratory therapies.

Mankind Pharma’s branded product portfolio is extensive and includes well-known brands such as Nurokind, Telmikind, Manforce, Gudcef, Moxikind, Amlokind, and many others. These brands cater to various healthcare needs, including women’s health, fertility, and critical care. The company’s products are designed to provide effective healthcare solutions to patients, and its portfolio is constantly evolving to meet the changing needs of the healthcare industry.

In addition to its pharmaceutical products, Mankind Pharma also has a strong presence in the consumer healthcare segment, offering a range of products that cater to everyday health needs. The company’s subsidiaries, including Lifestar Pharma Private Limited, Magnet Labs Private Limited, and Jaspack Industries Private Limited, contribute to its overall growth and expansion.

With a strong focus on research and development, Mankind Pharma is committed to innovation and quality, ensuring that its products meet the highest standards of safety and efficacy. The company’s manufacturing facilities are equipped with state-of-the-art technology, and its quality control processes are rigorous and stringent.

Overall, Mankind Pharma Limited is a reputable and trusted name in the Indian pharmaceutical industry, known for its high-quality products, innovative approach, and commitment to customer satisfaction. With a strong product portfolio, extensive distribution network, and dedicated team, the company is well-positioned to continue its growth trajectory and make a significant impact in the global healthcare industry. Through its subsidiaries and branded products, Mankind Pharma is dedicated to providing effective healthcare solutions to patients and improving the quality of life for people around the world.